Maraviroc Inhibits SARS-CoV-2 Through Variant-Dependent Effects on Viral Entry and Mpro Activity Using Single-Round Infectious Particle and Virus-like Particle Models
It is demonstrated that MVC exerts variant-dependent antiviral effects by targeting viral entry, modulating trafficking pathways, and inhibiting Mpro activity against SARS-CoV-2 variants, providing insights into its potential therapeutic application.